Brief: Alterity Therapeutics Presents Ath434-201 Phase 2 Clinical Trial Results At European Msa Symposium
28/04/2025 13:11
April 28 (Reuters) - Alterity Therapeutics Ltd ATH.AX: ALTERITY THERAPEUTICS PRESENTS ATH434-201 PHASE 2 CLINICAL TRIAL RESULTS AT EUROPEAN MSA SYMPOSIUM Source text: ID:nGNXVHnVF Further company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital